M34.2 identifies systemic sclerosis (scleroderma) that is directly attributable to exposure to a drug or chemical agent, distinguishing it from idiopathic or progressive systemic sclerosis subtypes.
Verified May 8, 2026 · 5 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 0
- Region
- General
Documentation tips
What should appear in the chart to support M34.2.
Source · Editorial brief grounded in 5 cited references ↓
- Identify the specific drug or chemical by name and document the provider's explicit statement linking the substance to the onset of systemic sclerosis.
- Specify whether the exposure was a poisoning, an adverse effect of a correctly prescribed drug, or an underdosing — this determines T-code selection and sequencing order.
- Document all active systemic manifestations (e.g., pulmonary involvement, renal crisis, polyneuropathy) with their own codes to support CC/MCC capture and accurate DRG assignment.
- Record the timeline of exposure relative to symptom onset so the causal relationship is auditable in the medical record.
- If the exposure has resolved but the sclerosis persists, document 'sequela of drug/chemical exposure' and sequence accordingly using the 7th character S on the T-code.
Common coding pitfalls
The recurring mistakes coders make with M34.2 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Assigning M34.2 without the required companion T36–T65 or T36–T50 code — the tabular instructs 'code first' or 'use additional code' and omitting it is an incomplete code set.
- Confusing adverse effect sequencing with poisoning sequencing: adverse effect puts M34.2 first; poisoning puts the T-code first — reversing this order is a claim-level error.
- Using M34.2 for localized (circumscribed) scleroderma — the Excludes1 at M34 prohibits simultaneous use of L94.0 with any M34 code.
- Defaulting to M34.9 (unspecified) when the record clearly documents a drug or chemical cause — specificity is available and expected at M34.2.
- Failing to code systemic manifestations separately, which collapses a potentially MCC-weighted encounter to a lower DRG tier.
Clinical context
Source · Editorial summary grounded in 5 cited references ↓
M34.2 applies when the clinical record establishes a causal link between a specific drug or chemical exposure and the development of systemic sclerosis. The diagnosis requires documented exposure to the offending agent and a provider's stated determination that the substance induced the sclerotic process. This code sits under parent category M34 (Systemic sclerosis [scleroderma]) and shares the category-level Excludes1 restrictions: do not use M34.2 for circumscribed scleroderma (L94.0) or neonatal scleroderma (P83.88).
M34.2 carries mandatory sequencing instructions that govern how it appears on the claim. When the exposure is a poisoning, sequence the poisoning code from T36–T65 (with 5th or 6th character 1–4) first, then M34.2. When the exposure is an adverse effect of a correctly administered drug, sequence M34.2 first and add the appropriate adverse-effect code from T36–T50 (with 5th or 6th character 5) as an additional code. Skipping the companion T-code is the most common audit trigger for this diagnosis.
For MS-DRG assignment, M34.2 maps to DRG 545 (Connective tissue disorders with MCC), 546 (with CC), or 547 (without CC/MCC) under MS-DRG v43.0. Because systemic sclerosis carries significant multisystem comorbidity burden, documenting concurrent complications — pulmonary hypertension, interstitial lung disease, renal crisis, polyneuropathy — is critical for accurate CC/MCC capture and appropriate DRG weight.
Sibling codes
Other billable codes under M34 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 5 cited references ↓
01Does M34.2 always require a second code?
02What is the correct sequencing when the systemic sclerosis is an adverse effect of a properly prescribed drug?
03What is the correct sequencing when the systemic sclerosis results from a poisoning?
04Can M34.2 and L94.0 (circumscribed scleroderma) appear on the same claim?
05Which DRGs does M34.2 map to?
06Should M34.9 be used when the causative agent is known?
07Does M34.2 apply to neonatal scleroderma caused by a drug exposure in the mother?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (effective October 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M30-M36/M34-/M34.2
- 03aapc.comhttps://www.aapc.com/codes/icd-10-codes/M34.2
- 04icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M30-M36/M34-
- 05cdc.govhttps://www.cdc.gov/nchs/icd/icd-10-cm/index.html
Mira Scribe
Mira AI Scribe captures the specific drug or chemical implicated, the nature of exposure (adverse effect vs. poisoning), the provider's documented causal statement linking the substance to systemic sclerosis, and any active multisystem manifestations (pulmonary, renal, neurologic). This prevents incomplete code sets that omit the required T-code companion, incorrect sequencing between M34.2 and the T-code, and loss of CC/MCC-eligible comorbidity codes that affect DRG weight.
See how Mira captures M34.2 documentation